| P2093 | author name string | Stanley Lipkowitz | |
| | Allan M. Weissman | |
| P2860 | cites work | Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1 | Q22008789 |
| | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| | RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination | Q22010577 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Identification of a cryptic nucleolar-localization signal in MDM2 | Q22253304 |
| | Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 | Q22253350 |
| | HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Q24291102 |
| | C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation | Q24291783 |
| | Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex | Q24292279 |
| | The TRC8 ubiquitin ligase is sterol regulated and interacts with lipid and protein biosynthetic pathways | Q24294805 |
| | E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1) | Q24296663 |
| | Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. | Q33925815 |
| | Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development | Q33946999 |
| | The p53 orchestra: Mdm2 and Mdmx set the tone | Q34020353 |
| | The genetic basis of kidney cancer: a metabolic disease | Q34087148 |
| | Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells | Q34136434 |
| | Deregulated degradation of the cdk inhibitor p27 and malignant transformation. | Q34167777 |
| | Parc: a cytoplasmic anchor for p53. | Q34170344 |
| | BRCA1 and BRCA2 and the genetics of breast and ovarian cancer | Q34189009 |
| | Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu | Q34190181 |
| | Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. | Q34277639 |
| | Structural model of the UbcH5B/CNOT4 complex revealed by combining NMR, mutagenesis, and docking approaches. | Q34310787 |
| | Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations | Q34317446 |
| | Tumor suppression and normal aging in mice with constitutively high p53 activity | Q34324057 |
| | Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. | Q34368432 |
| | Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors | Q34379259 |
| | Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer | Q34609774 |
| | Role of FLT3 in leukemia | Q34664542 |
| | CUL7 is a novel antiapoptotic oncogene | Q34702306 |
| | Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. | Q34761024 |
| | BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP | Q34863348 |
| | Alterations of anaphase-promoting complex genes in human colon cancer cells | Q24297514 |
| | Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL | Q24299061 |
| | UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation | Q24300065 |
| | WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase | Q24316117 |
| | Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase | Q24316238 |
| | The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8 | Q24320007 |
| | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| | Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 | Q24328775 |
| | An essential function of the extreme C-terminus of MDM2 can be provided by MDMX | Q24328822 |
| | CUL7: A DOC domain-containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex | Q24336508 |
| | Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | Q24336712 |
| | Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2 | Q24337575 |
| | Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents | Q24337605 |
| | A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair | Q24337655 |
| | Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3 | Q24538330 |
| | The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins | Q24564802 |
| | Role of the F-box protein Skp2 in lymphomagenesis | Q24603883 |
| | v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas | Q24624849 |
| | Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 |
| | How the fanconi anemia pathway guards the genome | Q24634556 |
| | Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity | Q24645473 |
| | Control of cell growth by the SCF and APC/C ubiquitin ligases | Q24647543 |
| | Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer | Q24648025 |
| | SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation | Q24653723 |
| | Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex | Q24654714 |
| | Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth | Q24800550 |
| | Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases | Q27626747 |
| | Structure of a BRCA1-BARD1 heterodimeric RING-RING complex | Q27635007 |
| | In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 |
| | Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans | Q27649717 |
| | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 |
| | Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 |
| | Regulation of p53 stability by Mdm2 | Q27860744 |
| | Wnt/beta-catenin signaling in development and disease | Q27860784 |
| | Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation | Q27860876 |
| | Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli | Q28116145 |
| | Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain | Q28119149 |
| | Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 |
| | The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7 | Q28138892 |
| | Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase | Q28139082 |
| | MDM2 interacts with MDMX through their RING finger domains | Q28142437 |
| | The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase | Q28145635 |
| | Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7 | Q28146026 |
| | Oncogenic kinase signalling | Q28189493 |
| | Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex | Q28199187 |
| | Role of direct interaction in BRCA1 inhibition of estrogen receptor activity | Q28204456 |
| | The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation | Q28207617 |
| | ErbB2 degradation mediated by the co-chaperone protein CHIP | Q28208008 |
| | Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein | Q28214794 |
| | Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells | Q28253606 |
| | The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 | Q28266637 |
| | Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia | Q28267951 |
| | E2 conjugating enzymes must disengage from their E1 enzymes before E3-dependent ubiquitin and ubiquitin-like transfer | Q28270616 |
| | Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 |
| | Control of chromosome stability by the beta-TrCP-REST-Mad2 axis | Q28273354 |
| | Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5 | Q28276949 |
| | The Cbl interactome and its functions | Q28277251 |
| | Association of BRCA1 with Rad51 in mitotic and meiotic cells | Q28302118 |
| | Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase | Q28506124 |
| | Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation | Q28609772 |
| | Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase | Q28617041 |
| | Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway | Q28910446 |
| | Blinded by the Light: The Growing Complexity of p53 | Q29547590 |
| | Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 |
| | Brca1 controls homology-directed DNA repair | Q29614844 |
| | Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein | Q29615928 |
| | HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability | Q29615945 |
| | FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation | Q29616127 |
| | Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 | Q29617290 |
| | Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 | Q29617850 |
| | Ubiquitin ligases: cell-cycle control and cancer | Q29617992 |
| | The anaphase promoting complex/cyclosome: a machine designed to destroy | Q29618398 |
| | Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 |
| | c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor | Q29618661 |
| | Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage | Q29619360 |
| | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 |
| | Nucleolar Arf sequesters Mdm2 and activates p53 | Q29620244 |
| | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 |
| | The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme | Q30156839 |
| | Novel roles of hakai in cell proliferation and oncogenesis | Q30489228 |
| | Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. | Q33209208 |
| | CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases | Q33528991 |
| | BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha | Q33576505 |
| | The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells | Q33652431 |
| | c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase/Akt pathway | Q33796333 |
| | Oncogenic activation of NF-kappaB. | Q33849388 |
| | Proteasome inhibitors in cancer therapy | Q34939959 |
| | Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 |
| | The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity | Q35201819 |
| | Signaling to p53: ribosomal proteins find their way. | Q35206381 |
| | The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity | Q35610627 |
| | Ablation of Cbl-b provides protection against transplanted and spontaneous tumors | Q35664087 |
| | Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase | Q35749504 |
| | Skp2 is oncogenic and overexpressed in human cancers | Q35862209 |
| | Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity | Q35865833 |
| | Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells | Q36002265 |
| | Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. | Q36155317 |
| | Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells | Q36229277 |
| | FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors | Q36229551 |
| | HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. | Q36347917 |
| | Regulating the regulator: negative regulation of Cbl ubiquitin ligases | Q36365848 |
| | Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity | Q36732343 |
| | Therapeutic targets in the ARF tumor suppressor pathway. | Q36879301 |
| | Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. | Q36986557 |
| | IAPs as a target for anticancer therapy. | Q37065372 |
| | Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity | Q37283603 |
| | Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene | Q37285776 |
| | Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein | Q37286026 |
| | The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma | Q37306830 |
| | Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma | Q37314736 |
| | Ubiquitin in trafficking: the network at work | Q37325110 |
| | BRCA1 and its toolbox for the maintenance of genome integrity | Q37507563 |
| | Mdm2-mediated ubiquitylation: p53 and beyond. | Q37508606 |
| | The multiple levels of regulation by p53 ubiquitination | Q37526379 |
| | Siah proteins: novel drug targets in the Ras and hypoxia pathways | Q37634198 |
| | COP1 is a tumour suppressor that causes degradation of ETS transcription factors | Q39542337 |
| | MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer | Q39548990 |
| | Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma | Q39560187 |
| | BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. | Q39580598 |
| | Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions | Q39605573 |
| | The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. | Q39762239 |
| | CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. | Q39874787 |
| | Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis | Q39875666 |
| | The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation | Q40044913 |
| | The ubiquitin ligase SCF(betaTrCP) regulates the degradation of the growth hormone receptor | Q40133210 |
| | A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation | Q40133909 |
| | Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist | Q40202330 |
| | Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells | Q40410781 |
| | Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. | Q40585447 |
| | Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms | Q40773986 |
| | Cbl-b regulates the CD28 dependence of T-cell activation. | Q40904107 |
| | Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 |
| | The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair | Q41914934 |
| | BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer | Q42477044 |
| | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms | Q42795736 |
| | Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 |
| | Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain | Q42815138 |
| | MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. | Q43052729 |
| | Mutation of the RAD51C gene in a Fanconi anemia-like disorder | Q43094703 |
| | Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein | Q44043145 |
| | The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma | Q44043146 |
| | Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation | Q44420471 |
| | Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. | Q44896717 |
| | Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. | Q45179048 |
| | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 |
| | PARC and CUL7 form atypical cullin RING ligase complexes. | Q50336204 |
| | BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. | Q52537650 |
| | Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. | Q53265333 |
| | Genomic stability and tumour suppression by the APC/C cofactor Cdh1. | Q53471624 |
| | Myeloid Leukemia Development in c-Cbl RING Finger Mutant Mice Is Dependent on FLT3 Signaling | Q54642331 |
| | Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. | Q54680719 |
| | Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. | Q55476278 |
| | SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype | Q55671559 |
| | Flt3-dependent transformation by inactivating c-Cbl mutations in AML | Q57269958 |
| | Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b | Q59058408 |
| | Cancer predisposing BARD1 mutations in breast-ovarian cancer families | Q64386906 |
| | cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors | Q73133553 |
| | BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg? | Q79207429 |
| | Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide | Q79733375 |
| | Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families | Q82528631 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 629-43 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis | |
| P478 | volume | 11 | |